ArticleInfection and drug resistance2026
Development and Evaluation of a Duplex Lateral Flow Immunoassay for Rapid Detection of KPC and NDM Carbapenemases.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Direct-from-Specimen Detection of Major Carbapenemases by Carbapenem-Resistant K.N.I.V.O. Detection K-Set: Comparative Analysis of Accuracy and Turnaround Time.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Enterobacterales represent a critical global health challenge, with KPC and NDM being the most prevalent carbapenemase families. Rapid and reliable detection tools are essential for guiding infection control and antimicrobial stewardship, particularly in resource-limited settings. Methods: A lateral flow immunoassay (LFIA) strip was developed for simultaneous detection of KPC and NDM carbapenemases. Monoclonal antibody pairs were screened and assay parameters were optimized to improve analytical performance. Analytical evaluation was performed using recombinant proteins. Clinical evaluation was conducted using 12 non-duplicate clinical Results: The LFIA achieved limits of detection of 0.5 ng/mL for KPC and 0.1 ng/mL for NDM using recombinant proteins. No cross-reactivity was observed with other carbapenemases (OXA-48, VIM, IMP). In the clinical Conclusion: This duplex LFIA provides rapid, instrument-free visual screening for KPC and NDM carbapenemases in cultured isolates, supporting routine laboratory screening and workflow decisions. Larger multi-center studies across diverse Enterobacterales species and carbapenemase variants will further define its broader clinical performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.